Université de Lorraine, CITHEFOR, F-54000 Nancy, France; Nanocontrol, Nancy, France.
Université de Lorraine, CITHEFOR, F-54000 Nancy, France.
Int J Pharm. 2019 Oct 5;569:118583. doi: 10.1016/j.ijpharm.2019.118583. Epub 2019 Jul 31.
Nanoparticles are being developed for a wide range of medical applications such as, controlled release, drug delivery systems or imagery, theranostics, implants…. For the moment, there is no legal definition of nanoparticles or nanomaterials for therapeutic use. The specific case of gold nanoparticles is not an exception: their current definition as nanoparticle material does not correspond to classic pharmaceutical ingredients as described in Pharmacopoeias. In this study, more than 30 different batches of citrate stabilized gold nanoparticles (AuNP) were synthesized and analyzed thanks to both classical approaches (UV-Vis spectrophotometry, dynamic light scattering coupled or not to electrophoresis …) and capillary zone electrophoresis (CZE) coupled to diode array detection to assess their purity and impurity profiles. These techniques led to the beginning of defined specifications, a key step for the use of gold nanoparticles as pharmaceutical ingredients. CZE was demonstrated suitable to evaluate a batch-to-batch quality control, to monitor the purification processes and to follow the stability of 18 different batches for 20 days. Finally, commercially available AuNP samples were tested and the results compared to the provided certificates of analysis.
纳米粒子正在被开发用于广泛的医疗应用,如控制释放、药物传递系统或成像、治疗诊断、植入物等。目前,还没有治疗用途的纳米粒子或纳米材料的法律定义。金纳米粒子的特殊情况也不例外:它们目前作为纳米粒子材料的定义与药典中描述的经典药物成分不相符。在这项研究中,通过使用经典方法(UV-Vis 分光光度法、动态光散射结合或不结合电泳等)和毛细管区带电泳(CZE)结合二极管阵列检测,合成并分析了 30 多批柠檬酸钠稳定的金纳米粒子(AuNP),以评估其纯度和杂质分布。这些技术为确定规格奠定了基础,这是将金纳米粒子用作药物成分的关键步骤。CZE 被证明适合评估批间质量控制,监测纯化过程,并在 20 天内跟踪 18 批不同批次的稳定性。最后,对市售的 AuNP 样品进行了测试,并将结果与提供的分析证书进行了比较。